News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna's next-gen COVID shot gets FDA backing with some limitations
Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its next-gen shot, mNEXSPIKE. | Moderna has picked up its third FDA approval with the agency's endorsement of mNEXSPIKE.
The vaccine is expected to remain available for anyone who is at least 65 or who has a medical condition, leaving many ...
Limiting access stops healthy adults and children living with elderly or immunocompromised family members from choosing to do ...
The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback